Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746068 | 1.00 | LMNA (0.61) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL9855964 | 0.91 | LMNA (0.71) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL9855968 | 0.91 | LMNA (0.71) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL6747013 | 0.89 | LMNA (0.49) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL6747017 | 0.89 | LMNA (0.49) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL20719894 | 0.87 | AKR1B10 (0.71) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL20719893 | 0.87 | AKR1B10 (0.71) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL15673280 | 0.85 | LMNA (0.63) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL10071614 | 0.85 | LMNA (0.63) | LMNAAKR1B10AKR1B1GLATDP1 | |
| SCHEMBL1192078 | 0.85 | LMNA (0.63) | LMNAAKR1B10AKR1B1GLATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720445-B2 | PHENYLPROPIOLOYLOXYMETHYL ACETATE, FOR EXAMPLE; TREATING CANCER, HEMOLOGICAL DISORDERS AND INHERITED METABOLIC DISORDERS; INHIBITORS OF HISTONE DEACETYLASE | BEACON LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6699902-B2 | ANTICANCER AGENTS | BEACON LABORATORIES, INC. | 2004-03-02 | — | — | US | disclosed |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | ERRANT GENE THERAPEUTICS, LLC | 2002-10-31 | — | — | US | disclosed |
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | BEACON LABORATORIES, A DELAWARE CORPORATION | 2002-08-29 | — | — | US | disclosed |
| EP-1216984-A1 | Novel acetyloxymethyl esters and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | AADAC, ACAT1, EP300 | LMNA 1914/4885AKR1B10 455/4885AKR1B1 426/4885 |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | AADAC, ACAT1, EP300 | LMNA 1914/4885AKR1B10 455/4885AKR1B1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.